Petra Stieber1, Dorothea Nagel1, Irene Blankenburg1, Volker Heinemann2, Michael Untch3, Ingo Bauerfeind4, Dorit Di Gioia5. 1. Institute of Laboratory Medicine, Klinikum Großhadern, University Hospital, 81377 Munich, Germany. 2. Department of Internal Medicine III, Klinikum Großhadern, University Hospital, 81377 Munich, Germany. 3. Gynecological Department, Helios Klinikum, 13125 Berlin-Buch, Germany. 4. Gynecological Department, Klinikum Landshut, 84034 Landshut, Germany. 5. Department of Internal Medicine III, Klinikum Großhadern, University Hospital, 81377 Munich, Germany. Electronic address: dorit.digioia@med.uni-muenchen.de.
Abstract
OBJECTIVE: We investigated the diagnostic capacity of CEA and CA 15-3 kinetics for the early detection of metastatic disease in comparison to fixed cut off values. METHODS: In a retrospective analysis, a total of 743 patients with early breast cancer and available baseline values of CEA and CA 15-3 were included. A reproducible increase of 100% of single or combined markers was considered as a strong indicator of metastatic disease. RESULTS: 187 patients developed metastatic disease and 556 remained disease-free. On the basis of tumor marker kinetics, we reached a specificity of >98% for both biomarkers and a sensitivity of 40.6% for CEA alone, 55.6% for CA 15-3 alone and 66.3% for the combination of both markers. Using fixed cut-off values (CEA: 4ng/mL, CA 15-3: 30U/mL) we ended up with a specificity of 86.3% and a sensitivity of 70.6% for the combination of CEA and CA 15-3. Using higher cut-off values (CEA: 6ng/mL, CA 15-3: 60U/mL) we reached a specificity of 96.9% and a sensitivity of 49.7% for the combination. CONCLUSION: We conclude that the interpretation of these markers in follow-up using individual baseline values and kinetics leads to a significant superior profile of specificity and sensitivity.
OBJECTIVE: We investigated the diagnostic capacity of CEA and CA 15-3 kinetics for the early detection of metastatic disease in comparison to fixed cut off values. METHODS: In a retrospective analysis, a total of 743 patients with early breast cancer and available baseline values of CEA and CA 15-3 were included. A reproducible increase of 100% of single or combined markers was considered as a strong indicator of metastatic disease. RESULTS: 187 patients developed metastatic disease and 556 remained disease-free. On the basis of tumor marker kinetics, we reached a specificity of >98% for both biomarkers and a sensitivity of 40.6% for CEA alone, 55.6% for CA 15-3 alone and 66.3% for the combination of both markers. Using fixed cut-off values (CEA: 4ng/mL, CA 15-3: 30U/mL) we ended up with a specificity of 86.3% and a sensitivity of 70.6% for the combination of CEA and CA 15-3. Using higher cut-off values (CEA: 6ng/mL, CA 15-3: 60U/mL) we reached a specificity of 96.9% and a sensitivity of 49.7% for the combination. CONCLUSION: We conclude that the interpretation of these markers in follow-up using individual baseline values and kinetics leads to a significant superior profile of specificity and sensitivity.
Authors: Mohit Jain; Shailesh D Ingole; Rahul S Deshmukh; Simin V Bharucha; Anagha S Nagvekar; Rajiv V Gaikwad; Shambhudeo D Kharde Journal: Chromosome Res Date: 2021-02-27 Impact factor: 5.239
Authors: Emily Powell; Jiansu Shao; Hector M Picon; Christopher Bristow; Zhongqi Ge; Michael Peoples; Frederick Robinson; Sabrina L Jeter-Jones; Christopher Schlosberg; Caitlin L Grzeskowiak; Fei Yang; Yun Wu; Ignacio Wistuba; Stacy L Moulder; William F Symmans; Kenneth L Scott; John R Edwards; Han Liang; Timothy P Heffernan; Helen Piwnica-Worms Journal: NPJ Breast Cancer Date: 2018-04-30